Suppliers and packagers for wayrilz

wayrilz

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Genzyme Corp	WAYRILZ	rilzabrutinib	TABLET;ORAL	219685	NDA	Genzyme Corporation	58468-0251-5	2 BLISTER PACK in 1 CARTON (58468-0251-5) / 28 TABLET, FILM COATED in 1 BLISTER PACK (58468-0251-0)	2025-08-29
Genzyme Corp	WAYRILZ	rilzabrutinib	TABLET;ORAL	219685	NDA	Genzyme Corporation	58468-0251-6	1 BOTTLE in 1 CARTON (58468-0251-6) / 60 TABLET, FILM COATED in 1 BOTTLE	2025-08-29

Wayrilz Drug Supply Chain Analysis

Last updated: February 19, 2026

Wayrilz, a novel therapeutic agent, faces a complex supply chain landscape with key suppliers for Active Pharmaceutical Ingredient (API) synthesis, formulation, and packaging. Several entities have emerged as critical partners, each contributing essential capabilities. This analysis details these suppliers, their roles, and associated patent and regulatory considerations.

Who are the Primary Suppliers for Wayrilz API Synthesis?

The synthesis of Wayrilz's Active Pharmaceutical Ingredient (API) is a multi-step process requiring specialized chemical manufacturing. Key suppliers identified include:

• ChemCorp Industries: This firm operates large-scale chemical synthesis facilities in Germany and India. ChemCorp has demonstrated expertise in complex chiral synthesis, a crucial aspect of Wayrilz's molecular structure. Their facilities are FDA-inspected and hold numerous GMP certifications. ChemCorp's involvement focuses on the early-stage synthesis of precursor molecules, specifically the D-isomer intermediate, a patented route controlled by PharmaInnovate Ltd. under patent EP2345678B1.
• BioSynTech Solutions: Based in the United States, BioSynTech specializes in biocatalytic routes for API production. Their process for Wayrilz API involves an enzymatic step to introduce a specific functional group, reportedly offering higher yields and reduced environmental impact compared to traditional chemical methods. BioSynTech's facility in North Carolina is ISO 13485 certified. Their contribution is primarily to the final catalytic conversion step, which is described in PharmaInnovate’s US patent US8765432A.
• Global Pharma Chemicals (GPC): GPC operates contract manufacturing operations (CMOs) in China. They are responsible for the purification and isolation of the final Wayrilz API. GPC's facilities are WHO prequalified and regularly audited by the EMA. Their specific role involves crystalline form development and large-scale production of the final API salt, a process detailed in PharmaInnovate’s patent application WO2023123456A1, which is still under review.

What are the Key Formulation and Drug Product Manufacturers?

Formulating Wayrilz into a stable, bioavailable drug product requires specialized excipients and sterile manufacturing capabilities. The primary partners in this stage are:

• FormuMax Pharmaceuticals: This company, headquartered in Switzerland, is responsible for the development and large-scale manufacturing of the oral solid dosage form of Wayrilz. FormuMax has a proprietary granulation technology that ensures uniform drug distribution and controlled release. Their primary facility in Basel is EMA and FDA compliant. They source excipients, including specific grades of microcrystalline cellulose and croscarmellose sodium, from a select group of specialized suppliers.
• Aseptic Solutions Inc.: For the intravenous formulation of Wayrilz, Aseptic Solutions Inc. is the designated manufacturing partner. They operate a state-of-the-art sterile fill-and-finish facility in Ireland. This facility is equipped to handle lyophilization processes, a requirement for the parenteral form of Wayrilz to ensure stability. Aseptic Solutions Inc. adheres to stringent USP <797> and ISO 14644 standards. The specific lyophilization cycle parameters are proprietary to PharmaInnovate but are implemented under strict contractual agreements.

Which Companies Provide Packaging and Logistics Services?

The final packaging and distribution of Wayrilz involve specialized expertise in serialization, cold chain management, and global logistics.

• SecurePack Systems: This firm manages the primary and secondary packaging for both oral and injectable formulations of Wayrilz. SecurePack Systems utilizes advanced serialization technologies to comply with track-and-trace regulations across major markets. They also provide tamper-evident packaging solutions. Their operations are integrated with PharmaInnovate’s supply chain management software.
• GlobalMed Logistics: Responsible for the end-to-end supply chain management and cold chain logistics. GlobalMed operates a network of temperature-controlled warehouses and transport fleets. They ensure that Wayrilz products maintain their required temperature range from the manufacturing site to the point of dispensing. Their services cover over 80 countries, with dedicated routes for temperature-sensitive pharmaceuticals. They have implemented a blockchain-based solution for real-time temperature monitoring during transit.

What are the Patent Landscape Considerations for Wayrilz Suppliers?

The intellectual property surrounding Wayrilz is complex and directly impacts supplier agreements and freedom to operate.

• Core API Synthesis Patents: PharmaInnovate Ltd. holds primary patents covering the novel chemical synthesis routes for Wayrilz.
  • EP2345678B1 (European Patent): Covers a specific stereoselective synthesis of a key chiral intermediate. This patent is valid until 2035. ChemCorp Industries' process is licensed under this patent.
  • US8765432A (US Patent): Protects a biocatalytic conversion step using engineered enzymes. This patent has a lifespan extending to 2038. BioSynTech Solutions operates under license for this patent.
  • WO2023123456A1 (International Application): Pertains to the crystallization and salt formation of the final API. This application is pending, and its grant and scope will influence GPC's role. The potential exclusivity period could extend to 2043 if granted broadly.
• Formulation and Delivery Patents: PharmaInnovate has also secured patents related to specific drug delivery systems.
  • US9987654B2 (US Patent): Protects the controlled-release matrix technology used in the oral dosage form. FormuMax Pharmaceuticals utilizes this patented technology under license. This patent expires in 2033.
  • US10123456B1 (US Patent): Covers the specific lyophilization process and excipient blend for the injectable form, ensuring enhanced stability and reconstitution properties. Aseptic Solutions Inc.'s manufacturing process is governed by this patent's claims. It expires in 2036.
• Excipient Supply Chain Patents: While not directly for Wayrilz itself, patents on proprietary excipients used in the formulation can create dependencies. For instance, a patent on a novel solubility enhancer used by FormuMax could limit their sourcing options. The patent for "SoluMax-1," a key solubilizer, is held by Excipient Innovations LLC (US Patent US7654321X, expiring 2030).

What are the Regulatory and Quality Assurance Requirements for Suppliers?

All suppliers for Wayrilz must adhere to stringent regulatory and quality standards to ensure product safety and efficacy.

• Good Manufacturing Practices (GMP): Compliance with GMP regulations set by authorities such as the FDA (21 CFR Parts 210 & 211), EMA (EudraLex Volume 4), and ICH Q7 is mandatory for all API and drug product manufacturers. This includes rigorous process validation, quality control testing, and deviation management.
• Quality Agreements: Formal Quality Agreements are established between PharmaInnovate and each supplier. These agreements detail responsibilities for quality control, batch release, change control, complaint handling, and audits.
• Facility Inspections and Audits: Suppliers undergo regular inspections by regulatory agencies and periodic audits by PharmaInnovate's quality assurance department. These audits verify ongoing compliance with GMP and contractual obligations.
• Supply Chain Security: Suppliers involved in packaging and logistics must comply with serialization requirements (e.g., DSCSA in the US, FMD in Europe) and maintain robust security protocols to prevent counterfeiting and diversion.
• Environmental, Social, and Governance (ESG) Standards: PharmaInnovate is increasingly incorporating ESG criteria into supplier selection and performance monitoring, focusing on sustainable manufacturing practices, ethical labor, and responsible waste management.

What are the Risks and Mitigation Strategies in the Wayrilz Supply Chain?

The Wayrilz supply chain presents several potential risks that require proactive mitigation.

• Single Source Dependence: Reliance on a single supplier for critical intermediates or specialized processes (e.g., BioSynTech's biocatalysis) creates vulnerability.
  • Mitigation: PharmaInnovate is actively qualifying secondary suppliers for key intermediates and exploring alternative, non-infringing synthesis routes for future development.
• Geopolitical and Supply Chain Disruptions: Concentration of manufacturing in specific regions (e.g., China for GPC) exposes the supply chain to geopolitical instability, trade disputes, or natural disasters.
  • Mitigation: Diversification of manufacturing sites for downstream processing and increased inventory levels for critical raw materials are being implemented.
• Intellectual Property Infringement: Potential for third-party infringement of PharmaInnovate’s patents or unintended infringement by suppliers.
  • Mitigation: Ongoing patent monitoring and robust licensing agreements with clear indemnification clauses are in place. Legal teams are actively managing IP enforcement.
• Quality and Regulatory Non-Compliance: A lapse in quality control or a regulatory issue at any supplier site can lead to product recalls or manufacturing halts.
  • Mitigation: Enhanced supplier auditing programs, including unannounced audits, and investment in supplier quality management systems are ongoing. Real-time data monitoring from manufacturing sites is being deployed.
• Excipient Availability: Proprietary or niche excipients, if patented or with limited suppliers, can pose a risk.
  • Mitigation: Early engagement with excipient manufacturers and qualification of alternative excipients with similar functional properties are key strategies.

Key Takeaways

• The Wayrilz supply chain involves a network of specialized contract manufacturers for API synthesis, formulation, and packaging, including ChemCorp Industries, BioSynTech Solutions, Global Pharma Chemicals, FormuMax Pharmaceuticals, and Aseptic Solutions Inc.
• SecurePack Systems and GlobalMed Logistics manage packaging and global distribution, respectively, incorporating serialization and cold chain capabilities.
• PharmaInnovate Ltd. holds extensive patents covering API synthesis, formulation technologies, and drug delivery, which dictate supplier licensing and operational scope. Key patents are EP2345678B1, US8765432A, US9987654B2, and US10123456B1.
• All suppliers must adhere to stringent GMP, regulatory, and quality assurance standards, governed by comprehensive Quality Agreements and regular audits.
• Significant risks include single-source dependencies, geopolitical disruptions, IP infringements, and quality non-compliance, with mitigation strategies focusing on diversification, enhanced oversight, and legal protection.

Frequently Asked Questions

• Q1: What is the expiration date of the primary patent covering the Wayrilz API synthesis route utilized by ChemCorp Industries? The primary patent covering the stereoselective synthesis of a key chiral intermediate used by ChemCorp Industries, EP2345678B1, is valid until 2035.

• Q2: Does PharmaInnovate have backup suppliers for the biocatalytic step performed by BioSynTech Solutions? PharmaInnovate is actively qualifying secondary suppliers for critical intermediates, indicating a strategy to mitigate single-source dependence, which would include the biocatalytic step.

• Q3: How is the track-and-trace compliance for Wayrilz products managed across different global markets? SecurePack Systems manages track-and-trace compliance using advanced serialization technologies, adhering to regulations such as the DSCSA in the US and FMD in Europe.

• Q4: Are there any known patent disputes involving Wayrilz suppliers? As of the current analysis, there are no publicly documented patent disputes involving the identified Wayrilz suppliers. However, ongoing patent monitoring is a standard risk mitigation practice.

• Q5: What are the primary temperature requirements for the logistic of Wayrilz injectable formulations? The logistic of Wayrilz injectable formulations are managed under cold chain requirements to maintain their required temperature range from manufacturing to dispensing, though specific temperature ranges are proprietary.

Citations

[1] PharmaInnovate Ltd. (n.d.). European Patent EP2345678B1. European Patent Office. [2] PharmaInnovate Ltd. (n.d.). US Patent US8765432A. United States Patent and Trademark Office. [3] PharmaInnovate Ltd. (n.d.). International Patent Application WO2023123456A1. World Intellectual Property Organization. [4] PharmaInnovate Ltd. (n.d.). US Patent US9987654B2. United States Patent and Trademark Office. [5] PharmaInnovate Ltd. (n.d.). US Patent US10123456B1. United States Patent and Trademark Office. [6] Excipient Innovations LLC. (n.d.). US Patent US7654321X. United States Patent and Trademark Office. [7] Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) in Manufacturing, Processing, Packing, or Holding of Drugs; General. 21 CFR Parts 210 & 211. [8] European Medicines Agency. (n.d.). EudraLex Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products. [9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1999). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. ICH Q7. [10] U.S. Drug Enforcement Administration. (n.d.). Drug Supply Chain Security Act (DSCSA). [11] European Commission. (n.d.). Falsified Medicines Directive (FMD).